Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
25
IPSEY Quote, Financials, Valuation and Earnings
Last price:
$34.94
Seasonality move
:
2.32%
Day range:
$34.94 - $34.94
52-week range:
$25.11 - $38.95
Dividend yield:
1.14%
P/E ratio:
23.89x
P/S ratio:
3.01x
P/B ratio:
2.08x
Volume:
13
Avg. volume:
2K
1-year change:
23.33%
Market cap:
$11.6B
Revenue:
$3.7B
EPS (TTM):
$1.48
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Ipsen SA has -- downside to fair value with a price target of -- per share.
IPSEY vs. S&P 500
-
Over the past 5 trading days, Ipsen SA has underperformed the S&P 500 by -3.22% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ipsen SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ipsen SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Ipsen SA reported revenues of --.
Earnings Growth
-
Ipsen SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ipsen SA reported earnings per share of --.
Enterprise value:
9.5B
EV / Invested capital:
--
Price / LTM sales:
3.01x
EV / EBIT:
13.85x
EV / Revenue:
2.29x
PEG ratio (5yr expected):
6.60x
EV / Free cash flow:
14.43x
Price / Operating cash flow:
27.77x
Enterprise value / EBITDA:
6.63x
Gross Profit (TTM):
$3.2B
Return On Assets:
6.8%
Net Income Margin (TTM):
12.68%
Return On Equity:
11.08%
Return On Invested Capital:
9.54%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $893.3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.1B | $2.7B | $1.9B | $2B | $3.3B | |
| Total Assets | $5.4B | $5.8B | $6.6B | $7B | $8B | |
| Current Liabilities | $1.3B | $1.4B | $1.9B | $1.8B | $1.7B | |
| Total Liabilities | $2.5B | $2.5B | $2.9B | $2.7B | $3B | |
| Total Equity | $2.8B | $3.2B | $3.7B | $4.3B | $5B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-27 | 2024-12-27 | 2024-12-27 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
IPSEY
Sector
Market Cap
$11.6B
$27.8M
Price % of 52-Week High
89.71%
51.03%
Dividend Yield
1.14%
0%
Shareholder Yield
1.69%
-1.55%
1-Year Price Total Return
27.94%
-17.47%
Beta (5-Year)
0.433
0.518
Dividend yield:
1.14%
Annualized payout:
$0.33
Payout ratio:
-25.82%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$35.22
200-day SMA
Buy
Level
$32.05
Bollinger Bands (100)
Buy
Level
32.9 - 36.2
Chaikin Money Flow
Sell
Level
-1.3M
20-day SMA
Sell
Level
$35.54
Relative Strength Index (RSI14)
Sell
Level
37.36
ADX Line
Sell
Level
17.23
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$35.63
MACD (12, 26)
Sell
Level
-0.26
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-307.9K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4663)
Buy
CA Score
(Annual)
Level (0.8056)
Buy
Beneish M-Score
(Annual)
Level (-2.9374)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-1.7841)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.
Stock Forecast FAQ
In the current month, IPSEY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IPSEY average analyst price target in the past 3 months is --.
-
Where Will Ipsen SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ipsen SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Ipsen SA?
Analysts are divided on their view about Ipsen SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ipsen SA is a Sell and believe this share price will rise from its current level to --.
-
What Is Ipsen SA's Price Target?
The price target for Ipsen SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IPSEY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ipsen SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of IPSEY?
You can purchase shares of Ipsen SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ipsen SA shares.
-
What Is The Ipsen SA Share Price Today?
Ipsen SA was last trading at $34.94 per share. This represents the most recent stock quote for Ipsen SA. Yesterday, Ipsen SA closed at $34.94 per share.
-
How To Buy Ipsen SA Stock Online?
In order to purchase Ipsen SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get IPSEY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IPSEY
Sector
P/E ratio
23.89x
23.89x
PEG ratio
6.60x
-0.01x
P/B ratio
2.08x
1.82x
Price / LTM sales
3.01x
1.60x
Growth Metrics
IPSEY
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.88%
Revenue (5-year growth)
4.99%
6.5%
Earnings forecast
--
-$0.21
Profitability
IPSEY
Sector
Profitability FY 2024
$2.7B
$3.5M
Return on invested capital
9.54%
-31.77%
Return on assets
6.8%
-27.96%
Return on equity
11.08%
-37.63%
Earnings Date
Last Earnings Date
Jul
31
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Oct
30
Balance Sheet
IPSEY
Sector
Total cash
$1.7B
$26.3M
Short term investments
$1.1M
$25.7M
Total assets
$6.7B
$78M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 27
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
